SCHLIEREN, SWITZERLAND – InSphero AG, the leading provider of ready-to-test 3D cell culture models, entered into an agreement with Pfizer Inc.NYSE: PFE ), one of the largest biopharmaceutical companies in the world, to develop a new predictive toxicology test using InSphero 3D InSight � human liver micro-tissue. This new in vitro mechanical test will aim to build on the increased sensitivity and longevity of InSphero’s 3D hepatic models, which could allow multiplexing of several evaluation criteria to help detect and predict toxicity mechanisms medication.
Dr. Jan Lichtenberg, CEO and co-founder of InSphero, said: “Our 3D liver model allows researchers to better predict toxicity and potential side effects using more biologically relevant cellular tests. Could also help reduce dependency on animal models, add significant costs, delay time to market, and often fail to accurately reflect the human response to a drug. Pfizer and this new agreement will allow the development of tests possessing potentially even more utility and predictive power for the early development of drugs by Pfizer. “
Dr. Simon Messner, who will lead the project for InSphero, added: “The longevity and organotypic nature of 3D InSight � human liver microfibers are closely correlated with those of the native liver, exhibiting cellular organization, response to The cytochrome P450 enzyme and appropriate metabolic functionality, and the use of this 3D model could result in higher levels of accuracy and accuracy in the in vitro prediction of some LHIM mechanisms.
The agreement entered into force in April 2017 and involves scientists in the United States (Brunswick, Maine) and facilities in Schlieren (Switzerland) of InSphero, with contributions from Pfizer scientists.
Source: Insphero AG